ABSTRACT
Chroman derivatives exhibited potent inhibitory activity of NF-kappaB. For SAR, the chroman scaffold was modified with an indoline moiety. A series of indoline-2-carboxylic acid N-(substituted)phenylamide derivatives were synthesized to explore their inhibitory activities of NF-kappaB and they were also evaluated for cytotoxicity against various cancer cell lines. Since intermediates with Boc showed outstanding results, various substituents in place of the Boc group were introduced additionally and these compounds were also evaluated for SAR.
Subject(s)
Antineoplastic Agents/chemistry , Benzylamines/chemistry , Indoles/chemistry , Antineoplastic Agents/chemical synthesis , Antineoplastic Agents/toxicity , Benzylamines/chemical synthesis , Benzylamines/toxicity , Cell Line, Tumor , Chromans/chemistry , Drug Screening Assays, Antitumor , Humans , NF-kappa B/antagonists & inhibitors , NF-kappa B/metabolism , Structure-Activity RelationshipABSTRACT
A series of 2-alkyl-2,3-dihydro-1H-2,6-diazacyclopenta[b]anthracene-5,10-diones (4a-f) was synthesized and their in vitro cytotoxic activities were evaluated against six human cancer cell lines (HCT15, SK-OV-3, SNB19, A549, MCF7 and MCF7/ADR). They all appeared to be less potent than doxorubicin against all doxorubicin sensitive human cancer cell lines tested. However, these compounds retained considerable cytotoxic activity against the doxorubicin-resistant cell line MCF7/ADR, implying their therapeutic potential to treat doxorubicin-resistant tumors. The most active compound 4c was equipotent with doxorubicin against HCT15 cell line.